Skip to main content

Table 1 Patient characteristics

From: Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy

Time point Dx Last measurement prior to start of IV iloprost
Subjects (n) 50 50
Age (years) 42 (29-58) 44 (31-63)
Interval diagnosis and initiation of iloprost (month)   34 (20-47)
Female/male 34/16 34/16
NYHA class II/III/IV 7/30/13 1/24/24
6MWD (m) 332 (229-434) 289 (132-370) #
PAH-specific therapy Initial therapy  
Sildenafil alone 11 (22%) 0 (0%)
ERA alone 22 (44%) 2 (4%)
Inhaled Iloprost alone 8 (16%) 0 (0%)
Sildenafil + ERA 6 (12%) 14 (28%)
Sildenafil + inhaled Iloprost 3 (6%) 3 (6%)
ERA + inhaled Iloprost 0 (0%) 5 (10%)
Triple therapy 0 (0%) 26 (52%)
Hemodynamics n = 50 n = 26
PRA (mmHg) 7 (3-13) 12 (7-16) #
Ppa (mmHg) 59 (48-68) 56 (49-65)
Ppcw (mmHg) 7 (5-9) 9 (7-11)
CI (L/min/m2) 2.0 (1.5-2.3) 1.7 (1.4-1.9)
PVR (dyn*s*cm-5) 1, 251 (852-1, 705) 1, 205 (954-1, 499)
SVO2 (%) 58 (54-66) 58 (54-69)
  1. Characteristics at diagnosis (Dx) and start of intravenous iloprost. Absolute values are given regarding PAH-specific therapy, functional class and gender. Age, interval from Dx to BL-ilo, 6MWT and hemodynamic parameters are given as median (interquartile range; IQR). #: p < 0.05 vs Dx.